In conclusion, we demonstrated that IGF2BP1 modified CDC5L mRNA in an m6A-dependent way to promote the proliferation of MM cells with 1q+ and provide novel preclinical evidence of targeting the IGF2BP1/CDC5L axis for effective control of MM development. The gene discussed is IGF2BP1; the disease is Miyoshi myopathy.